EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function

EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function

Abstract Background Cutaneous adverse drug reactions (CADR) associated with oncology therapy involve 45–100% of patients receiving kinase inhibitors. Such adverse reactions may include skin inflammation, infection, pruritus and dryness, symptoms that can significantly affect the patient’s quality of...

Full description

Bibliographic Details
Main Authors: Nicolas Joly-Tonetti, Thomas Ondet, Mario Monshouwer, Georgios N. Stamatas
Format: Article
Language:English
Published: BMC 2021-01-01
Series:BMC Cancer
Subjects:
Cutaneous adverse drug reactions
Oncology therapy
Tyrosine kinase inhibitors
Skin barrier impairment
Keratinocyte differentiation
Epidermal growth factors receptor inhibitors
Online Access:https://doi.org/10.1186/s12885-020-07685-5

Internet

https://doi.org/10.1186/s12885-020-07685-5

Similar Items